upifitamab rilsodotin

DRUG3 trials

Sponsors

Mersana Therapeutics

Conditions

Non Small Cell Lung Cancer MetastaticNon-Small Cell AdenocarcinomaPlatinum Resistant Ovarian Cancer

Phase 1

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruitingNCT03319628

Mersana TherapeuticsNon Small Cell Lung Cancer Metastatic, Platinum Resistant Ovarian Cancer

Start: 2017-12-12End: 2024-10-31Updated: 2023-11-13

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

CompletedNCT06517485

Mersana TherapeuticsNon-Small Cell Adenocarcinoma, Platinum Resistant Ovarian Cancer

Start: 2019-07-30End: 2022-08-03Updated: 2024-07-24

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

CompletedNCT06517433

Mersana TherapeuticsNon Small Cell Lung Cancer Metastatic, Platinum Resistant Ovarian Cancer

Start: 2017-12-12End: 2021-07-09Updated: 2024-07-24

Related Papers

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Molecular Cancer Therapeutics2023-06-0931 citations

33 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

Gynecologic Oncology Reports2022-12-012 citations

TP036/#426 Uplift (ENGOT-OV67/GOG-3048) a pivotal cohort of the XMT-1536–1 trial of upifitamab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

2022-12-011 citations

32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer

Gynecologic Oncology Reports2022-12-011 citations

Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.

Journal of Clinical Oncology2021-05-2011 citations

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2020-05-2015 citations

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.

Journal of Clinical Oncology2019-05-2018 citations